Applications of molecular biology and biotechnology: Antibody therapy of sepsis

Journal of Critical Care

Volumn 11, Issue 2, 1996, Pages 77-94

  Wheeler, Arthur P ^a   Bernard, Gordon R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC REACTION; HUMAN; IMMUNOTHERAPY; MOLECULAR BIOLOGY; REVIEW; SEPSIS;

EID: 0030037207     PISSN: 08839441     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0883-9441(96)90023-4     Document Type: Note

References (102)

1. von Behring E: Zur Behandlung der Diptherie mit Diptherie Heilserum. Deutsche Med Wochenschr 19:543-544, 1893
2. McClelland DBL, Yap PL: Clinical use of Immunoglobulins. Clin Haematol 13:39-74, 1984
3. Borrebaeck CAK, Larrick JW: Therapeutic Monoclonal Antibodies. New York, NY, Stockton 1990 pp 33-46
4. Schifferli JA: Adverse effects of intravenous Immuno-globulins. Transfusion Sci 13:331-338, 1992
5. Malasit P, Warrell DA, Chanthavanich P, et al: Prediction, prevention and mechanism of early (anaphylactic) antivenom reactions in victims of snake bites. Br Med J 292:17-20, 1986
6. Seeff CB, Hoofnagle JH: Immunoprophylaxis of viral hepatitis. Gastroenterology 77:161-182, 1979
7. Pollack W, Gorman JG, Freda VJ: Prevention of Rho hemolytic disease. Progr Hematol 6:121,1969
8. Hooks MA, Wade CS, Millikan WJ: Muromonab CD-3: A review of its pharmacology, pharmacokinetics and clinical use in transplantation. Pharmacotherapy 11:26-37, 1991
9. Baldwin RW, Byers VS: Monoclonal Antibodies for Cancer Detection and Therapy. London, UK, Academic, 1985
10. Male D, Champion B, Cooke A: Advanced Immunology, (ed 2). London, UK, Gower Medical, 1992
11. Roitt I, Brostoff J, Male D: Antibody Structure and Function, in: Roitt I, Brostoff J, Male D, (eds): Immunology. London, UK, Mosby: 1993, pp 5.1-5.8
12. Chapel H, Heaney M: Essentials of Clinical Immunology (ed 3). Oxford, UK, Blackwell Scientific, 1993
13. Buchowicz I, Goch H, Zakrzewski: Equine Immunoglobulins: A comparison of molecular properties. Acta Biochem Polon 16:279-294, 1969
14. Harlow E, Lane D: Antibodies: A Laboratory Manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1988, pp 53-135
15. Roitt I, Brostoff J, Male D: Hypersensitivity: Type III, in Roitt I, Brostoff J, and Male D, (eds): Immunology. London, UK, Mosby, 1993, pp 21.1-21.10
16. Bellanti JA: Immunology II. Philadelphia, PA, WB Saunders, p 157
17. Harlow E, Lane D: Antibodies: A Laboratory Manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1988, pp 283-312
18. Smith TW, Loyd BL, Spicer N, et al: Immunogenicity and kinetics of distribution and elimination of sheep digoxin-speciflc IgG and Fab fragments in the rabbit and baboon. Clin Exp Immunol 36:384-396, 1979
19. Kohler G, Howe SC, Milstein C: Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines. Eur J Immunol 6:292-295, 1976
20. Berzofsky JA, Berkower IJ: Antigen-antibody interaction, In Paul WE (ed): Fundamental Immunology New York, NY, Raven 1984, pp 595-644
21. Carroll SB, Thalley BS, Theakston RDG, Laing G: A comparison of the purity and efficacy of affinity purified avian snake antivenoms with commercial equine crotalid antivenoms. Toxicon, 30:1017-1025, 1992
22. Baumgartner JD: Antiendotoxin monoclonal antibodies: Lessons learned from recent clinical trials. Clin Immunother 1:8-14, 1994
23. Heumann D, Baumgartner JD, Jacot-Guillarmod H, et al: Antibodies to core lipopolysaccharide determinants: Absence of cross-reactivity with heterologous lipopolysaccharides. J Infect Dis 163:762-768, 1991
24. Campbell AM: Monoclonal Antibody Technology: The Production and Characterization of Rodent and Human Hybridomas. Elsevier Science Publishers, Amsterdam, Netherlands, 1985, pp 110-174
25. Card J, Smith TW, Jaton JC, et al: The isolation of digoxin-specific antibody and its use in reversing the effects of digoxin. Proc Natl Acad Sci USA 68:2401-2406, 1979
26. Landon J, Chard T, Coxon RE: An introduction to the clinical applications of antibodies, in Landon J, Chard T, (eds): Therapeutic Antibodies. London, UK, Springer Verlag, 1995, p 29
27. Theakston RDG, Smith DC: Therapeutic antibodies to snake venoms, in Landon J, Chard T (eds): Therapeutic Antibodies. London, UK, Springer Verlag, 1995, pp 109-133
28. Kirkpatrick CH: The digibind study advisory panel. Allergic histories and reactions of patients treated with digoxin immune Fab (ovine) antibody. Am J Emerg Med 9:7-9, 1991
29. LoBuglio AF, Wheeler RH, Trang J, et al: Mouse/ human chimeric monoclonal antibody in man: Kinetics and immune response. Proc Natl Acad Sci USA 85:4220-4224, 1989
30. Hale G, Dyer MJS, Clark MR, et al: Remission induction in non-Hodgkins lymphoma with reshaped human monoclonal antibody Campath-1H. Lancet 2:1394-1399, 1988
31. Lesslauer W, Tabuchi H, Gentz R, et al: Recombinant soluble tumor necrosis factor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immun 21:2883-2886, 1991
32. Ashkenazi A, Marsters SA, Capon DJ, et al: Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci USA 88:10535-10539, 1991
33. Williams RC: Immune complexes in Clinical and Experimental Medicine. Cambridge, MA, Harvard Press, 1980, pp 109-141
34. Mayes JT, Thistlewhite JR, Stuart, et al: Reexposure to OKT3 in renal allograft recipients. Transplantation 45:349, 1988
35. Greenman RL, Shein RMH, Martin MA, et al: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatments of Gram-negative sepsis. JAMA 266:1097-1102, 1991
36. Fisher CJ, Opal SM, Dhainaut JF, et al: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care 21:318-327, 1993
37. Ziegler EJ, McCutchan JA, Fierer J, et al: Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coil. N Engl J Med 307:1225-1230, 1982
38. Baumgartner JD, Glauser MP, McCuthan JA, et al: Prevention of Gram-negative shock and death in surgical patients by prophylactic antibody to endotoxin core glycolipid. Lancet 2:59-63, 1985
39. Luce JM: Introduction of new technology into critical care practice: A history of HA1A human monoclonal antibody against endotoxin. Crit Care Med 21:1233-1241, 1993
40. Wood DM, Parent JB, Gazzano-Santoro H, et al: Reactivity of monoclonal antibody E5 with endotoxin I. Binding to lipid A and rough lipopolysaccharides. Circ Shock 38:55-62, 1992
41. Parent JB, Gazzano-Santoro H, Wood DM, et al: Reactivity of monoclonal antibody E5 with endotoxin II. Binding to short- and long-chain smooth lipopolysaccharides. Circ Shock 38:63-73, 1992
42. st Conference Antimicrobial Agents and Chemotherapy Am Soc Microbiology, Washington, DC, 1991 (abstr 788)
43. Marra MN, Thornton MB, Snabble, et al: Endotoxin binding and neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA1A and E5. Crit Care Med 22:559-565, 1994
44. Wheeler AP, Hardie WD, Bernard GR: Studies of an antiendotoxin antibody in preventing the physiologic changes of endotoxemia in awake sheep. Am Rev Respir Dis 142:775-781, 1990
45. Bouter AS, van Kessel KPM, Cornelissen JJ, et al: Inability of lipid A murine specific monoclonal antibody E5 to neutralize lipopolysaccharide biological activity in vitro. Serodiag Immuno Infect Dis 6:35-39,1994
46. Chen TY, Zapol WM, Greene E, et al: Protective effects of E5 and antiendotoxin monoclonal antibody, in the ovine pulmonary circulation. J Appl Physiol 75:233-229, 1993
47. Warren HS, Amato SF, Fitting C, et al: Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J Exp Med 177:89-97, 1993
48. Wheeler AP, Wheeler LA, Morris P, Bernard GR: Failure of endotoxin antibodies in murine endotoxemia. Chest 102:S155, 1992
49. Romulo RL, Palardy JE, Opal SM: Efficacy of antiendotoxin monoclonal antibody E5 alone or in combination with ciprofoloxacin in neutropenic rats with Pseudomonas sepsis. J Infect Dis 167:126-130, 1993
50. Young LS, Gascon R, Alam S, et al: Monoclonal antibodies for therapy of Gram-negative infections. Reviews Infect Dis 11:S1564-1571, 1989 (suppl 7)
51. th Medeteranian Cong of Chemo, Athens, Greece. May 24-29, 1992
52. Harkonen S, Scannon P, Mischak RP, et al: Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and non-bacteremic patients. Antimicrob Agents Chemo 32:710-716, 1988
53. Greenberg RN, Wilson KM, Kunz AY, et al: Randomized double blind Phase II study of antiendotoxin antibody (E5) as adjuvant therapy in humans with serious Gramnegative infections, in Sturk A, van Deventer SJH (eds): Bacterial Endotoxins. Wiley-Liss, New York, NY, 1991, pp 179-186
54. Greenberg RN, Wilson KM, Kunz AY, et al: Observations using anti-endotoxin antibodies (E5) as adjuvant therapy in humans with suspected serious Gram-negative sepsis. Crit Care Med 20:730, 1992
55. Bone RC, Balk RA, Fein AM, et al: A second large controlled clinical study of E5 a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 23:994-1005, 1995
56. Bogard WC, Siegel SA: The human monoclonal antibody HA1A: Studies on the epitope location within the endotoxin molecule and epitopic structure on the surface of viable gram-negative bacteria. Circ Shock 34:119, 1991 (abstr)
57. Teng NNH, Kaplan HS, Hebert JM: Protection against Gram-negative bacteremia and endotoxin with human monoclonal IgM antibodies. Proc Natl Acad Sci USA 82:1790-1794, 1985
58. Ziegler EJ, Teng NNNH, Douglas H, et al: Treatment of Pseudomonas bacteremia in neutropenic rabbits with human monoclonal IgM antibody against E Coli lipid A. Clin Res 35:619, 1987, (abstr)
59. Baumgartner J, Heumann D, Gerain J, et al: Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6: Comparison of O side chain specific antibodies with core LPS antibodies. J Exp Med 171:889-896, 1990
60. Baumgartner JD, Heumann D, Glauser MP: The HA1A monoclonal antibody for gram negative sepsis. N Engl J Med 325:281-282, 1991 (letter)
61. Feeley TW, Minty BD, Scuydder CM, et al: The effect of human antiendotoxin monoclonal antibodies on endotoxin induced lung injury in the rat. Am Rev Resp Dis 135:665-670, 1987
62. Tune BM, Hsu CY, Bieber MM, Teng NN: Effects of anti-lipid A human monoclonal antibody on lipopolysaccharide induced toxicity to the kidney. J Urol 141:1463-1466, 1989
63. Quezado ZM, Natanson C, Ailing DW, et al: A controlled trial of HA1A in a canine model of gram negative septic shock. JAMA 269:2221-2227,1993
64. Khazaeli MB, Wheeler R, Rogers K, et al: Initial evaluation of a human immunoglobulin M monoclonal antibody (HA1A) in humans. J Biol Resp Modifiers 9:178-184, 1990
65. Fisher CJ, Zimmerman J, Khazaeli B: Initial evaluation of human monoclonal antilipid A antibody (HA1A) in patients with sepsis syndrome. Crit Care Med 18:1311-1315, 1990
66. Waldman TA, Stober W, Blaese RM: Metabolism of Immunoglobulins, in Amos B (ed): Progress in Immunology. New York, NY, Academic, 1971, pp 891-903
67. Steis RG, Carrasquillo JA, McCabe R, et al: Toxicity, immunogenicity and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma. J Clin Oncol 8:476-490, 1990
68. Ziegler EJ, HA-1A Sepsis Study Group: Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibodies against endotoxin: A randomized double blind placebo controlled trial. N Engl J Med 324:429-36, 1991
69. Kett DH, Quartin AA, Sprung CL, et al: An evaluation of the hemodynamic effects of HA1A human monoclonal antibody. Crit Care Med 22:1227-1234, 1994
70. Wortel CH, von der Mohlen MA, van Deventer SJ, et al: Effectiveness of a human monoclonal anti-endotoxin antibody (HA1A) in Gram-negative sepsis: Relationship to endotoxin and cytokine levels. J Infect Dis 166:1367-1374, 1992
71. National Committee for Evaluation of Centoxin: The French National registry of HA1A (Centoxin) in septic shock. A cohort study of 600 patient. Arch Int Med 154:2484, 1994
72. McCloskey RV, Straube RC, Sanders C, et al: Treatment of septic shock with human monoclonal antibody HA1A. A randomized double-blind, placebo controlled trial. Ann Int Med 121:1-5, 1994
73. Zaneti G, Heumann D, Gerain J, et al: Cytokine Production after intravenous or peritoneal gram-negative bacterial challenge in mice. J Immunol 148:1890-1897, 1992
74. Hinshaw LB, Tekamp-Olson P, Chang ACK, et al: Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF). Circ Shock 30:279-292, 1990
75. Fong Y, Tracey KJ, Moldawer LL, et al: Antibodies to cachectin/tumor necrosis factor reduce interleukin-1 and interleukin-6 appearance during lethal bacteremia. J Exp Med 170:1627, 1989
76. Mathison JC, Wolfson E, Ulevitch RJ: Participation of tumor necrosis factor in the mediation of bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 81:1925-1937, 1988
77. Beutler B, Milsarek IW, Cerami AC: Passive immunization against cachetin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869, 1985
78. Grau GE, Vesin C, DeGroote D, et al: Prevention of human TNF-induced cutaneous Shwartzman reaction and acute mortality in mice treated with anti-human TNF monoclonal antibodies. Clin Exp Immunol 84:411-414, 1991
79. Suva AT, Bayston KF, Cohen J: Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram-negative shock. J Infect Dis 162:421-427, 1990
80. Sheehan KCF, Ruddle NH, Schreiber RD: Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factor. J Immunol 142:3884-3893, 1989
81. Opal SM, Cross AS, Kelly NM, et al: Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas areuginosa. J Infect Dis 161:1148-1152, 1990
82. Opal SM, Cross AS, Sadoff JC, et al: Efficacy of antilipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudomonas Sepsis. J Clin Invest 88:885-890, 1991
83. Tracey KJ, Fong JY, Hesse DG, et al: Anti-Cachectin/ TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330:662, 1987
84. Exley AR, Buurman W, Bodmer M, Bohen J: Monoclonal antibody (Mab) to recombinant human tumor necrosis factor (rhTNF) in the prophylaxis and treatment of endotoxic shock in Cynomolgus monkeys. Clin Sci 76:50, 1989 (abstr)
85. Exley AR, Cohen J, Buurman W, et al: Monoclonal antibodies to TNF in severe septic shock. Lancet 335:1275-1277, 1990 (letter)
86. Vincent JL, Bakker J, Marecaux G, et al: Administration if Anti-TNF antibody improves left ventricular function in septic shock patients: Results of a Pilot Study. Chest 101:810-815, 1992
87. Jesmock GJ, Lindsey C, Duerr M, et al: Efficacy of monoclonal antibody against human recombinant tumor necrosis factor in E Coli challenged swine. Am J Path 141:1197-1207, 1992
88. Fielder VB, Loof I, Sander E, et al: Monoclonal antibody to tumor necrosis factor alpha prevent lethal endotoxin sepsis in adult rhesus monkeys. J Lab Clin Med 120:574-588, 1992
89. Emerson TE, Lindsey DC, Jesmock GJ, et al: Efficacy of monoclonal antibody against tumor necrosis factor alpha in an endotoxemic baboon model. Circ Shock 38:75-84, 1992
90. Walsh CJ, Sugerman HJ, Mullen PG, et al: Monoclonal antibody to tumor necrosis alpha attenuates cardiopulmonary dysfunction in porcine gram negative sepsis. Arch Surg 127:138-145, 1992
91. Spooner C, Saravolatz L, Markowitz N, et al: Safety and pharmacokinetics of murine antibody to human tumor necrosis factor (TNF Mab). 31st Interscience Conf on Antimicrobial Agents Chemotherapy. Chicago, IL, Sept 29-Oct 2,1991 #541 Am Soc Micro.
92. Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. JAMA 273:934-941, 1995
93. Bodmer M: The generation and preclinical testing of CDP571: A humanized anti-TNF alpha antibody for therapeutic use. Abstr. Eur Cytokine Network 2:248, 1992 (suppl 3)
94. Engelberts I, Moller A, Leeuwenberg JFM, et al: Administration of tumor necrosis factor alpha (TNFalpha) inhibitors after exposure to TNFalpha prevents development of the maximal biological effect: An argument for clinical treatment with TNF alpha inhibitors. J Surg Res 53:510-514, 1992
95. Moller A, Emling F, Blohm D, et al: Monoclonal antibodies to human tumor necrosis factor alpha: in vitro and in vivo application. Cytokine 2:162-169, 1990
96. Kluge M, Kaul M: Tumor necrosis factor-neutralization with a specific monoclonal antibody, in Reinhart S (ed): Sepsis. London, UK, Springer Verlag, 1994, pp 337-356
97. Boekstegers P, Weidenhofer S, Zell R, et al: Repeated administration of a F(ab')2 fragment on an antitumor necrosis factor alpha monoclonal antibody in patients with severe sepsis: Effects on the cardiovascular system and cytokine levels. Shock 1:237-245, 1994
98. th Int Symposium Int Care and Emerg Med, Jewa, Germany
99. Eiselstein J: Personal communication. Washington DC, February 1995
100. Herbertson MJ, Werner HA, Goddard CM, et al: Anti-tumor necrosis factor alpha prevents decreased ventricular contractility in endotoxemic pigs. Am J Resp Crit Care Med 152:480-488,1995
101. th Interscience Congress - Antimicrobial Agents and Chemotherapy. Am Soc Microbiology, Washington DC, 1994, (abstr G66)
102. Starnes HF, Pearce MK, Rewari A, et al: Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor challenge in mice. J Immunology 145:4185-4191, 1990